Salt Lake City (Utah) [US], July 19: Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced grants awarded by the Bill & Melinda Gates Foundation r
Over the past ten years, an increase in head and neck malignancies has been related to human papillomavirus (HPV). For instance, studies show that 70 per cent of oropharyngeal cancer occurrences in the US are caused by HPV.
Human papillomavirus (HPV) has been linked to a rising number of head and neck cancers over the past ten years. For instance, research indicates that HPV is responsible for 70 per cent of oropharyngeal cancer cases in the US.
Adar Poonawalla said that the availability of the Human Papillomavirus (HPV) vaccine will be little in number this year, however, it would be boosted next year.
The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country, said Dr NK Arora, chairman of the Covid working group, National Technical Adviso
Cervical cancer is mostly related to human papillomavirus (HPV), and screening has made this cancer preventable. Yet, it is estimated that over 14,000 new cases will be diagnosed this year and more than 4,000 deaths will be attributed to cervical cancer.
India will soon introduce the human papillomavirus (HPV) vaccination to eliminate cervical cancer as a public health problem, said Dr Poonam Khetrapal Singh, World Health Organization (WHO) Regional Director for South-East Asia.
Approximately 16 billion vaccine doses, worth USD 141 billion, were supplied in 2021, almost three times the 2019 market volume (5.8 billion) and nearly three-and-a-half times the 2019 market value (USD 38 billion). The increase was primarily driven by COVID-19 vaccines, showing the incredib
New Delhi [India], October 21 (ANI): The production of India's first indigenously developed quadrivalent Human Papillomavirus (HPV) "CERVAVAC" vaccine, for the prevention of cervical cancer, by the Serum Institute of India will start in the first quarter of 2023 which got delayed due to C
New Delhi [India], August 31 (ANI): The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources told ANI.
New Delhi [India], July 12 (ANI): India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
Houston [US], June 22 (ANI): A recent study by researchers of UTHealth Houston discovered that using mushroom extract daily helps the immune system in clearing human papillomavirus (HPV) infections.